The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis

The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis

Mostra altre versioni (1)

**Background:** There are sparse data addressing whether standard risk factors for febrile neutropenia (FN) are relevant in patients receiving myelosuppressive chemotherapy and primary prophylaxis for FN, which would have implications for variables to consider during real-world comparative analyses...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Edward Li, Bridgette Kanz Schroader, David Campbell, Kim Campbell, Weijia Wang
Natura:	Articolo
Lingua:	English
Pubblicazione:	Columbia Data Analytics, LLC 2021-06-01
Serie:	Journal of Health Economics and Outcomes Research
Accesso online:	https://jheor.scholasticahq.com/article/24564-the-impact-of-baseline-risk-factors-on-the-incidence-of-febrile-neutropenia-in-breast-cancer-patients-receiving-chemotherapy-with-pegfilgrastim-prophy.pdf

Documenti analoghi

The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis
di: Edward Li, et al.
Pubblicazione: (2021-06-01)

Prophylaxis against febrile neutropenia with pegfilgrastim in Italy: a budget impact analysis
di: Giovanni Rosti, et al.
Pubblicazione: (2011-09-01)

On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: Current Status
di: Ivo Abraham, et al.
Pubblicazione: (2024-01-01)

Budget Saving Potential of Pegfilgrastim Biosimilar for the Treatment of Chemotherapy-Induced Febrile Neutropenia, in Italy
di: Patrizia Berto, et al.
Pubblicazione: (2022-02-01)

Incidence and Impact of Baseline Electrolyte Abnormalities in Patients Admitted with Chemotherapy Induced Febrile Neutropenia
di: Asim Jamal Shaikh, Samira Ahmed Bawany, Nehal Masood, Ausaf Ahmed Khan, Ahmed Nadeem Abbasi, Syed Najeeb Niamutullah, Adnan Zaidi, Salman Adil, Shiyam Kumar
Pubblicazione: (2011-01-01)

Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review
di: Girma Tekle Gebremariam, et al.
Pubblicazione: (2022-12-01)

An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer
di: Anbok Lee, et al.
Pubblicazione: (2023-12-01)

Pegfilgrastim on febrile neutropenia in pediatric and adolescent cancer patients: a systematic review and meta-analysis
di: Xia Zhu, et al.
Pubblicazione: (2023-12-01)

Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience
di: Shinya Tsuboi, et al.
Pubblicazione: (2023-01-01)

Effectiveness of pegfilgrastim prophylaxis in preventing febrile neutropenia during R-FC chemoimmunotherapy for chronic lymphocytic leukemia: A multicenter prospective phase II study
di: Youngwoo Jeon, et al.
Pubblicazione: (2023-03-01)

Prophylaxis and management of chemotherapy-induced febrile neutropenia: The role of myeloid growth factors
di: Dimitrijević Jelena, et al.
Pubblicazione: (2022-01-01)

Correction to: Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience
di: Shinya Tsuboi, et al.
Pubblicazione: (2023-04-01)

CHEMOTHERAPY-INDUCED NEUTROPENIA IN HIV POSITIVE PATIENTS WITH LYMPHOMA: COMPARISON OF PEGFILGRASTIM WITH DAILY FILGRASTIM ADMINISTRATION.
di: Luciana Teofili, et al.
Pubblicazione: (2012-01-01)

CHEMOTHERAPY-INDUCED NEUTROPENIA IN HIV POSITIVE PATIENTS WITH LYMPHOMA: COMPARISON OF PEGFILGRASTIM WITH DAILY FILGRASTIM ADMINISTRATION.
di: Luciana Teofili, et al.
Pubblicazione: (2012-10-01)

Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy
di: Zsuzsanna Kahan, et al.
Pubblicazione: (2019-02-01)

Identifying Risk Factors and Improving Preventive Strategies for Febrile Neutropenia in Children with Leukemia Receiving Ciprofloxacin Prophylaxis
di: Zühre Kaya, et al.
Pubblicazione: (2023-08-01)

NEUTROPENIA FEBRIL EN PEDIATRIA Febrile Neutropenia in Pedriatrics
di: Pio Lopez, et al.
Pubblicazione: (2008-03-01)

Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051
di: Keita Miura, et al.
Pubblicazione: (2024-02-01)

XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy
di: Topuzov E, et al.
Pubblicazione: (2008-11-01)

Febrile neutropenia recurrence after chemotherapy in patients with breast cancer
di: Simone Yuriko Kameo, Glebson Moura Silva, Namie Okino Sawada, Mary Elizabeth de Santana
Pubblicazione: (2020-10-01)

Update on Febrile Neutropenia in Pediatric Oncological Patients Undergoing Chemotherapy
di: Federica Cennamo, et al.
Pubblicazione: (2021-11-01)

Evaluation of Febrile Neutropenia in Hospitalized Patients with Neoplasia Undergoing Chemotherapy
di: Maria Bachlitzanaki, et al.
Pubblicazione: (2023-10-01)

Bloodstream infection in pediatric patients with febrile neutropenia induced by chemotherapy
di: Mariana Antunes Faria Lima, et al.
Pubblicazione: (2023-04-01)

Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update
di: Paola Villafuerte-Gutierrez, et al.
Pubblicazione: (2014-01-01)

Prescribing Empiric Antibiotics for Febrile Neutropenia: Compliance with Institutional Febrile Neutropenia Guidelines
di: Doaa Naeem, et al.
Pubblicazione: (2018-08-01)

Knowledge, attitude and practice towards chemotherapy-related neutropenia and febrile neutropenia among breast cancer patients
di: Yilin Chen, et al.
Pubblicazione: (2024-10-01)

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey [Corrigendum]
di: Innocenti R, et al.
Pubblicazione: (2019-02-01)

Respiratory distress and sudden death of a patient with GSDIb chronic neutropenia: possible role of pegfilgrastim
di: Jean Donadieu, et al.
Pubblicazione: (2009-08-01)

Uso do dispositivo Pegfilgrastim OBI para prevenção de neutropenia: revisão de escopo
di: Vivian do Prado Martins, et al.
Pubblicazione: (2023-08-01)

Corrigendum to “Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update”
di: Paola Villafuerte-Gutierrez, et al.
Pubblicazione: (2019-01-01)

Fluoroquinolone Prophylaxis Against Febrile Neutropenia in Areas With High Fluoroquinolone Resistance—An Asian Perspective
di: Esther Shu-Ting Ng, et al.
Pubblicazione: (2010-09-01)

Incidence of chemotherapy-induced neutropenia in HIV-infected and uninfected patients with breast cancer receiving neoadjuvant chemotherapy
di: Ngidi, S, et al.
Pubblicazione: (2017)

A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy‐induced neutropenia in patients with early‐stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study
di: Patrick Wayne Cobb, et al.
Pubblicazione: (2020-09-01)

Low albumin at the onset of febrile neutropenia predicts adverse outcome in pediatric febrile neutropenia
di: Manideepa Maji, et al.
Pubblicazione: (2022-01-01)

Level of Knowledge and Incidence of Emergency Oncology: Febrile Neutropenia in Hematologic Cancer Patients Post Chemotherapy: A Descriptive Study
di: Agus Suryaman
Pubblicazione: (2024-12-01)

Tratamiento ambulatorio del paciente con neutropenia febril Outpatient therapy in patients with febrile neutropenia
di: Andrés Londoño Gallo
Pubblicazione: (2008-01-01)

Predictive value of peri-chemotherapy hematological parameters for febrile neutropenia in patients with cancer
di: Hongyuan Jia, et al.
Pubblicazione: (2024-08-01)

Comparison of CISNE and MASCC Score in Predicting Complications on Post Chemotherapy Febrile Neutropenia
di: Sharifah Shakinah, et al.
Pubblicazione: (2024-07-01)

Pharmacokinetics and Pharmacodynamics of Cefepime in Adults with Hematological Malignancies and Febrile Neutropenia after Chemotherapy
di: José C. Álvarez, et al.
Pubblicazione: (2021-04-01)

Outcomes in 102 patients that present to the emergency department with chemotherapy-induced febrile neutropenia
di: Joo Han Lim, et al.
Pubblicazione: (2011-08-01)